Recurrent WHO Grade 2 Glioma
6 clinical trials · Condition
◉ Watch Recurrent WHO Grade 2 Glioma
| Record | Firm | Date |
|---|---|---|
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma (NCT04576117) | National Cancer Institute (NCI) | 2021-02-16 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
Track Recurrent WHO Grade 2 Glioma automatically
Every clearance here is in the API, with alerts when new ones post.